Abstract
Our results indicated that Silybin showed inhibition of prostate cancer and the mechanism was involving with downregulating ALDH1A1 expression, thereby inhibiting the activation of RARα and preventing the activation of Ets1 to inhibit the growth and invasion of prostate cancer.
Introduction
Prostate cancer remains one of the most prevalent malignancies in men globally. While Silybin, a flavonoid polyphenolic compound derived from milk thistle, has long been recognized for its antioxidant and anticancer properties, its precise molecular mechanism in prostate cancer was previously poorly understood.
A major challenge in treating prostate cancer is the presence of "cancer stem cells"—a subpopulation of cells that drive tumor growth, invasion, and resistance to therapy. Aldehyde dehydrogenase 1A1 (ALDH1A1) is a known marker for these aggressive cells. This study bridges the gap between Silybin’s known efficacy and its specific molecular targets, focusing on how it interacts with metabolic pathways to curb cancer progression.
Methodology
The researchers employed a multi-disciplinary approach combining bioinformatics with traditional laboratory experiments:
- Bioinformatics Screening: Using the PubChem database and the Subpathway-GM tool, 26 potential targets for Silybin were identified, eventually narrowing the focus to ALDH1A1 within the retinol metabolism pathway.
- Cell Sorting: Magnetic Bead Cell Sorting (MACS) was used to isolate ALDH1A1(+) and ALDH1A1(-) populations from the DU145 human prostate cancer cell line to study the most aggressive cancer cells.
- Functional and Molecular Assays: MTT assays evaluated proliferation, while Transwell and sphere-formation assays assessed migration and "stemness." Protein and mRNA expression levels of ALDH1A1, RARα, Ets1, and MMP9 were quantified via Western blotting and RT-PCR.
- In Vivo Validation: Tumors were implanted into BALB/c nude mice to observe the effects of Silybin on tumor volume and weight over a five-week period.
The Retinol Metabolism Pathway and ALDH1A1
The study identified the retinol metabolism pathway as the primary site of Silybin's intervention. ALDH1A1 plays a critical role in this pathway by converting retinal into retinoic acid, which subsequently activates nuclear receptors that drive gene expression related to cell growth and differentiation.
Key Results and Discussion
The ALDH1A1-RARα-Ets1 Axis
The most significant finding is the discovery of a regulatory "domino effect." ALDH1A1 expression is positively correlated with RARα (Retinoic Acid Receptor alpha) and Ets1 (a transcription factor). Silybin acts at the top of this chain; by inhibiting ALDH1A1, it prevents the activation of RARα and Ets1, which are crucial for cancer cell survival and spread.
Dose-Dependent Inhibition
Treatment with Silybin (50–200 µM) significantly reduced the expression of ALDH1A1 and RARα. This downregulation was mirrored by a decrease in Ets1 and MMP9, a protein associated with tissue remodeling and metastasis. Experimental data showed that ALDH1A1(+) cells, which constituted approximately 4.2% of the DU145 population, exhibited much higher proliferative and invasive capacity than ALDH1A1(-) cells, making them the primary target for Silybin's therapeutic effect.
In Vivo Success
In the BALB/c nude mouse model, Silybin treatment led to a visible and statistically significant reduction in both tumor volume (observable by day 10) and final tumor weight compared to the control group. Furthermore, using siRNA to knock down ALDH1A1 produced results similar to Silybin treatment, confirming that ALDH1A1 is the primary target of the compound's action.
Conclusion and Future Directions
Silybin demonstrates significant potential as a metabolic intervention for prostate cancer by targeting the "stemness" driven by ALDH1A1. However, several areas require further exploration:
- Bioavailability: Silybin often suffers from low bioavailability in humans. Future research should focus on delivery systems, such as nanoparticles, to ensure therapeutic concentrations reach the prostate.
- Clinical Translation: The in vitro experiments used concentrations up to 200 µM; determining if these levels are achievable and safe in human clinical trials is a necessary next step.
- Structural Characterization: While the ALDH1A1-RARα-Ets1 axis is clear, the exact physical binding or chemical interaction between Silybin and ALDH1A1 remains to be fully characterized at the structural level.
Summary updated